Congress narrows orphan drug exclusivity, risking rare-disease innovation
S. 3716 — RARE Act · Filed by Tammy Baldwin (D-WI) · Introduced Jan 28, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill narrows the 7-year market exclusivity period granted to drugs approved for rare diseases (orphan drugs). Instead of blocking all competing drugs for the same rare disease, the exclusivity now applies only to the specific approved use or indication—allowing competitors to market different treatments for the same rare disease or even the same drug for a different use within that disease. The change applies retroactively to all previously designated orphan drugs.
Why we flagged it
The bill's operative mechanism is a targeted amendment to orphan drug market exclusivity rules, narrowing the scope from disease-level to use/indication-level protection. This is a direct regulatory recalibration, not a broader deregulation or industry carve-out.
What the text implies
- Retroactive application to all previously designated orphan drugs may trigger immediate generic/biosimilar filings for existing drugs, potentially disrupting revenue streams for sponsors who relied on the broader exclusivity when they invested.
- Narrower exclusivity may reduce incentives for sponsors to pursue additional approved uses or indications within the same rare disease, since competitors can now enter with different uses without waiting out the 7-year period.
The full analysis lists 3 implications of this text.
Who stands to gain
generic drug manufacturers; biosimilar manufacturers; competing biopharmaceutical companies developing alternative rare-disease treatments